Abstract:2848 Background and Purpose: Melanoma has had a rising incidence in the United States over the past years. The aim of this study is to develop a novel protocol of stimulating immune response of melanoma carrying mice by irradiating and then surgical remove tumor to reduce melanoma metastatic disease.Methods:B16F0, mouse melanoma, in cell culture were irradiated with 25 Gy and incubated for 0, 6, and 24 hours, and then the cells growth on histological slides were fixed for CRT (calreculin), a potential immunogenicity of tumor cells, immunofluorescence staining. According to CRT expression following radiation from experiment 1, 1x 106 irradiated B16F0 cells were injected subcutaneously into the back neck of C57 mouse at 6 hours after 25 Gy. Control group were only received medium injection. 12 days after irradiated B16F0 vaccine injection, 0.8 x10 untreated B16F0 cells were implanted subcutaneously into the right hind limb on control and vaccine injection C57BL6/J mice. Tumor growth delay study were performed, and meanwhile B16F0 tumor tissues from control and vaccine injection mice were sampled for tumor-infiltrating lymphocytes (TIL) assay with whole mount histology technique for CD8+ T cell (cytotoxic T lymphocyte) detection. 0.5 x 106 B16F0 cells in 50 μl of medium were injected into the small previous made skin pouch on the right lateral abdomen of C57 mice. B16 F0 tumors (about 5-6 mm in diameter) of the irradiation + surgical remove group (6 mice) at 6 days after implantation were irradiated with 25 Gy. 300 ng of interleukin 2 was injected subcutaneously near tumor for the irradiation + surgical remove group at day 3 and 4 after irradiation. The tumor surgical remove group (5 mice) received shamed irradiation. The tumors were removed by surgery at day 5 after irradiation or shamed irradiation. 0.25 x 106 untreated B16F0 were injected each mouse through tail vein. The mice were sacrificed at day 12 after tail vein injection and the lungs were sampled for surface B16F0 nodes count. Results: CRT strongly expressed on the cell membrane surface of B16F0 after 25 Gy, 6 hours point had maximum expression. Irradiated B16F0 vaccine caused 5-7 days tumor growth delay comparing with the control group. The CD8+ T cell IHF staining showed that tumor infiltrating lymphocytes significantly appeared in B16F0 tumor tissues after irradiated B16F0 vaccine injection but control B16F0 tumor tissues had very few of CD8 + T cells positive staining. The counting of B16F0 nodes on lung surface resulted respectively the irradiation + surgical remove group: 4.2 ± 2.7, surgical remove group: 53.2 ± 9.5, and control group: 93.2 ± 17.1. Conclusion:Irradiated B16F0 vaccine can induce immune response that diminishes melanoma lung metastasis in mouse model.

Study of Anti-Melanoma Effect in Mice Injected with Melanoma Cells Transfected with the Recombinant Expressing Ag85A and GM-CSF

[Induction and Mechanism Study of Anti-Melanoma Immune Response by M. Tuberculosis Ag85B].

ANTITUMOR EFFECTS OF HUMAN IL-15 GENE MODIFIED LUNG CANCER CELL LINE

Cpg7909 Adjuvant Enhanced Immunogenicity Efficacy In Mice Immunized With Esat6-Ag85a Fusion Protein, But Does Not Confer Significant Protection Against Mycobacterium Tuberculosis Infection

Ag85B induces the antitumor immunity effect

Preliminary study on antitumor effect of C215gene transfected tumor vaccine and monoclonal antibody-superantigen fusion protein C 215Fab-SEA

Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma

Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation.

Inhibition of melanoma by survivin-specific lymphocytes combined with CCL17 and granulocyte-macrophage colony-stimulating factor in a mouse syngeneic model

[Development of HPV16 Positive Cervical Cancer Model in the Hu-Pbl-scid Mouse and Its Immunological Features].

Therapeutic Effect of Combined Treatment with CD Suicide Gene and GM-CSF Gene on Murine Melanoma and Its Immunological Mechanism

Antitumor effect of granulocyte-macrophage colony-stimulating factor (GM-CSF)-gene encoded vaccinia melanoma oncolysate and its immunological mechanisms

Enhanced Antitumor Effects of Tumor Antigen-Pulsed Dendritic Cells by Their Transfection with GM-CSF Gene.

Immunotherapy of Melanoma Metastasis by Adoptive Transfer of M-CSF Or/and IFN-γ Gene Modified Macrophages Pulsed with Tumor Extracts

Anti-neoplasm and immuno-modification effect of novel CpG oligodeoxynucleotides in mice

A study on anti-tumor immunity induced by gene-modified melanoma B16 cells.

Possible Reduction of Hepatoma Formation by Smmu 7721 Cells in Scid Mice and Metastasis Formation by B16f10 Melanoma Cells in C57bl/6 Mice by Agaricus Blazei Murill Extract

Anti-gastric carcinoma efficacy of gene modified dendritic cell vaccine recruited by macrophage inflammation protein-1

More vaccine efficacy studies on the recombinant bacille calmette-guerin co-expressing Ag85B, Mpt64 190-198 and Mtb8.4

Immune Response Induced by Irradiated B16F0 Vaccine Diminish Melanoma Lung Metastasis in Mouse Model

The Cell-mediated Immunoenhancement of Different Adjuvants on the Murine Melanoma Vaccine